Biocon Share Price in Focus After MHRA Approval for Insulin Unit in Malaysia

Biocon said on September 25 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its new drug product fill-finish unit for Semglee (insulin glargine) in Malaysia, as per the exhchange filing. 

The approval is for a new fill-finish line at the company’s insulin manufacturing facility in Malaysia. Biocon had already received approval from the European Medicines Agency (EMA) for the same line in July 2026.  

UK Regulator Approves New Insulin Unit 

The new unit will be used for Semglee, an insulin glargine product. The approval was granted by the UK’s MHRA for the drug product fill-finish facility.  

The facility is part of Biocon’s insulin manufacturing operations in Malaysia. 

EMA Had Approved the Line Earlier 

The MHRA approval comes after Biocon received clearance from the European Medicines Agency in July 2026. 

The company said the EMA had approved the new drug product fill-finish line earlier this year. 

Read More: ESDS Software Solution Share Price Hits 5% Lower Circuit After Q1 FY27 Earnings Results: Total Income Up 7.5% YoY! 

Biocon Share Price Performance  

As of 25 September 2026, at 12:50 PM, Biocon share price was trading at ₹383.90 per share, reflecting a decline of 0.96% from the previous trading session. 

Conclusion 

Biocon has now secured both UK and European regulatory approvals for its new insulin fill-finish line in Malaysia. The latest MHRA approval adds to the EMA clearance received in July and covers the unit that will be used for Semglee (insulin glargine). The company has not provided any further details on the commercial impact of the approval in its latest filing.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Turn insights into action - Open Free Demat Account with Angel One and start investing instantly.